Investors

Press Releases

Press Releases

Aug 09, 2022

Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update

Jul 27, 2022

Kymera Therapeutics to Report Second Quarter 2022 Results on August 9

Jul 08, 2022

Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

Jun 15, 2022

Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413

Jun 01, 2022

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma

Jun 01, 2022

Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis

May 20, 2022

Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting

May 05, 2022

Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation

May 03, 2022

Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update

Apr 19, 2022

Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences

Investor Contact

Bruce Jacobs, CFA, MBA
Chief Financial Officer
investors@kymeratx.com

Christopher F. Brinzey
Westwicke, an ICR Company for Kymera Therapeutics
chris.brinzey@westwicke.com
+ 1 339.970.2843

Media Contact

media@kymeratx.com

Tyler Gagnon
Director, Corporate Communications
tgagnon@kymeratx.com

Sign Up for Email Alerts